Technical foundation
100%U.S. route shell, noindex metadata, localized chrome, policy routes, and preview routing are in place.
Weight 15%
Loading...
A source-first U.S. drug experience for checking official identity, label readiness, and FDA approval context before any public medication guidance is published.
Last reviewed: June 12, 2026
Preview coverage
Completion is measured against the public MVP target: reviewed drug records, source-anchored question coverage, release approval, and invalid-traffic safety.
Readiness date: 2026-06-12
U.S. route shell, noindex metadata, localized chrome, policy routes, and preview routing are in place.
Weight 15%
12/12 target U.S. drug records are staged with reviewed source gates.
Weight 20%
300/300 target U.S. question previews are staged.
Weight 30%
300/300 question previews pass the source, FAQ, clinical boundary, and noindex audit.
Weight 10%
All drug gates are ready; the public index switch remains closed until operator approval.
Weight 15%
U.S. previews stay ad-free, affiliate-free, noindex, and excluded from active public-index surfaces while monitoring remains enabled.
Weight 10%
Next milestones
The U.S. experience stays noindex and ad-free until source promotion, reviewed patient copy, and indexing release checks all pass.
Global checks
Release blockers
Next release actions
Concrete source, copy, and review steps that must clear before the U.S. surface can move toward indexing.
Prepare the index release switch
highAll drug gates are ready across 18 candidate U.S. routes; keep sitemap, robots, and llms.txt closed until the operator-approved index release.
A dry-run view of what would open during the operator-approved index release. The active mode still keeps U.S. routes noindex and out of sitemap and llms.txt.
Audit date: 2026-06-12
Release surfaces
Audit checks
Candidate route manifest
passedThe U.S. index-release candidate set has 18 unique routes.
Current preview surfaces
passedCurrent U.S. mode keeps robots, sitemap, llms.txt, and route exclusion closed.
Public-index rehearsal
passedA public-index rehearsal would expose the same 18 candidate routes to sitemap and llms.txt.
Ads and affiliate posture
passedAds and affiliate surfaces stay closed even in the public-index rehearsal.
Keep preview locked until the operator explicitly approves the public-index release switch.
Three hundred source-anchored U.S. question previews are staged outside the public-index candidate manifest.
Acetaminophen and alcohol
Acetaminophen and alcohol should be treated as a higher-risk combination, especially with heavy or repeated drinking or when multiple products contain acetaminophen.
Open previewIbuprofen and alcohol
Ibuprofen and alcohol should be treated cautiously because both can raise concern for stomach irritation, bleeding, dizziness, or other adverse effects in some users.
Open previewAcetaminophen and ibuprofen
Acetaminophen and ibuprofen are different ingredients, but a user still needs product-label review to avoid duplicate ingredients, wrong dosing, or condition-specific risks.
Open previewOpen a sample record to inspect source readiness, review decisions, and publication blockers.
RxCUI 161 · IN
Release: ready
Open safety previewRxCUI 5640 · IN
Release: ready
Open safety previewRxCUI 11289 · IN
Release: ready
Open safety previewRxCUI 6809 · IN
Release: ready
Open safety previewRxCUI 1191 · IN
Release: ready
Open safety previewRxCUI 29046 · IN
Release: ready
Open safety previewRxCUI 10582 · IN
Release: ready
Open safety previewRxCUI 83367 · IN
Release: ready
Open safety previewRxCUI 36437 · IN
Release: ready
Open safety previewRxCUI 7646 · IN
Release: ready
Open safety previewRxCUI 8640 · IN
Release: ready
Open safety previewRxCUI 321988 · IN
Release: ready
Open safety previewStep 1
Anchor each U.S. page to RxNorm before label or approval records are attached.
Step 2
Use DailyMed SPL candidates to choose the label that should power future safety summaries.
Step 3
Treat Drugs@FDA and Orange Book records as review checkpoints, not as automatic publication evidence.